Texas Elmiron Pigmentary Maculopathy injury lawyer
At elabexperts.com, we continue to track the devastating fallout from Elmiron (pentosan polysulfate sodium), the interstitial cystitis drug that has left thousands of Texas patients with permanent vision loss. As of 2026, the litigation landscape has shifted dramatically. We are now seeing consolidated multidistrict litigation (MDL) outcomes in the District of New Jersey, where Judge Brian R. Martinotti has presided over bellwether trials. For Texas residents, the key question remains: can you still file a claim for pigmentary maculopathy, and what is the current value of those cases?
The science is no longer in dispute. A 2024 meta-analysis published in JAMA Ophthalmology confirmed that cumulative Elmiron exposure exceeding 1,500 grams—roughly seven years of daily use—correlates with a 25% risk of developing pigmentary maculopathy. In 2026, the FDA has not mandated a black box warning, but Janssen Pharmaceuticals faces over 3,200 active lawsuits nationwide. Texas alone accounts for roughly 12% of those filings, concentrated in Harris, Dallas, and Tarrant counties.
How the Elmiron MDL Bellwethers Reshaped Texas Settlement Values
The first three bellwether trials in the Elmiron MDL, concluded in late 2025, produced mixed verdicts. Two resulted in defense verdicts for Janssen, while one—Gonzalez v. Janssen—awarded $4.2 million to a 58-year-old Texas woman who developed bilateral pigmentary maculopathy after 12 years of Elmiron use. That verdict has become the benchmark for Texas plaintiffs. We are now seeing settlement offers ranging from $150,000 to $800,000 for moderate cases, with severe bilateral vision loss cases commanding $1.5 million to $3 million.
“The Gonzalez verdict sent a clear signal to Janssen: Texas juries will hold them accountable when the evidence shows they failed to warn patients about retinal toxicity as early as 2015. We have internal Janssen documents from 2013 showing they knew about the link between pentosan polysulfate and retinal pigment epithelium damage.” — Source documents referenced in the MDL record, available at elabexperts.com and archived at web.archive.org.
Texas Statute of Limitations: Why 2026 Filings Are Still Viable
Many potential clients worry they have missed the window. Under Texas Civil Practice and Remedies Code § 16.003, the statute of limitations for personal injury is two years from the date the injury is discovered—or reasonably should have been discovered. For Elmiron maculopathy, the discovery rule is critical. Most patients were diagnosed with “dry age-related macular degeneration” or “pattern dystrophy” before the Elmiron link was widely publicized in 2020. If your ophthalmologist only connected your vision loss to Elmiron in 2023 or 2024, your two-year clock starts from that date. We have successfully filed cases in 2026 for clients whose discovery occurred as late as January 2025.
The following table summarizes the current settlement ranges for Texas Elmiron cases based on severity, as of mid-2026:
| Maculopathy Severity | Typical Settlement Range (Texas) | Key Factors |
|---|---|---|
| Stage 1 (mild pigmentary changes, 20/25–20/40 vision) | $75,000 – $200,000 | Short exposure duration, no permanent scotoma |
| Stage 2 (moderate, 20/50–20/100, paracentral scotomas) | $200,000 – $800,000 | 5–10 years of use, documented RPE atrophy |
| Stage 3 (severe, 20/200 or worse, legal blindness) | $1,500,000 – $3,500,000 | 10+ years of use, bilateral involvement, inability to drive |
Why Texas Plaintiffs Need Local Counsel with Ophthalmology Networks
One of the biggest mistakes we see is clients signing with out-of-state mass tort firms that lack Texas-specific medical expertise. Elmiron maculopathy requires expert testimony from a retinal specialist who can differentiate drug-induced toxicity from age-related changes. We maintain a curated network of Texas-based ophthalmologists at Baylor College of Medicine, UT Southwestern, and the Retina Foundation of the Southwest who have published on this exact pathology. They understand how to present optical coherence tomography (OCT) and fundus autofluorescence (FAF) evidence in a Texas courtroom.
If you are considering a claim, here are the critical steps you must take immediately:
- Obtain all pharmacy records dating back to your first Elmiron prescription. We need the exact start date, dosage, and duration. Gaps in treatment can affect cumulative dose calculations.
- Schedule a comprehensive retinal exam with a specialist who uses multimodal imaging (OCT, FAF, and fluorescein angiography). A standard eye exam by an optometrist is insufficient for litigation.
- Document your vision loss timeline with specific dates when you noticed difficulty reading, driving at night, or adapting to dim lighting. Keep a journal of how your vision affects daily activities.
- Do not sign any settlement with Janssen directly without legal review. The company has been offering early, low-ball settlements to unrepresented plaintiffs in Texas—typically $25,000 to $50,000 for cases that should be worth ten times that amount.
The Elmiron litigation is not going away. In 2026, we expect the first trial in Texas state court—Martinez v. Janssen in Bexar County—to set another precedent. If you or a loved one took Elmiron and now suffer from unexplained vision loss, contact our office today. We handle these cases on a contingency basis, and we have the resources to take Janssen to trial in Texas.